Related Experiment Videos
Moxalactam pharmacokinetics during hemodialysis
Antimicrobial Agents and Chemotherapy
|April 1, 1981
Summary
Moxalactam elimination kinetics were studied in anephric patients. Hemodialysis significantly reduces moxalactam half-life, necessitating dose adjustments for patients with impaired kidney function.
Area of Science:
- Pharmacokinetics
- Nephrology
- Infectious Diseases
Background:
- Moxalactam is an antibiotic requiring dosage adjustments in renal impairment.
- Anephric patients undergoing hemodialysis present unique pharmacokinetic challenges.
Purpose of the Study:
- To determine moxalactam elimination kinetics in anephric patients.
- To establish evidence-based moxalactam dosage recommendations for patients on hemodialysis.
Main Methods:
- Studied moxalactam elimination in six anephric patients during hemodialysis and four during interdialysis.
- Administered a single 1-g intravenous bolus injection of moxalactam.
- Measured moxalactam half-life, volume of distribution, and plasma clearance.
Main Results:
- Moxalactam elimination half-life was 18.0 ± 0.6 h in non-dialyzed patients.
- Hemodialysis reduced moxalactam half-life to 2.7 ± 0.2 h.
- 48.5% of the moxalactam dose was removed during 4 hours of hemodialysis.
Conclusions:
- Moxalactam clearance is significantly increased during hemodialysis.
- Recommended maintenance dose should be 15% of normal for creatinine clearance <10 ml/min.
- A 50% loading dose post-hemodialysis is advised for anephric patients.